Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Synairgen Tests First Inhaled Candidate, No New China Cases

While Survey Shows Looming Crisis In Trial Recruitment

Executive Summary

More studies are being launched into possible treatments for patients hospitalised with COVID-19, with Roche launching a Phase III, placebo-controlled trial of Actemra.

You may also be interested in...



Synairgen Stock Soars 420% On Promise Of Inhaled COVID-19 Drug

Preliminary results show that hospitalized coronavirus patients who received Synairgen's inhaled interferon beta product had a 79% lower risk of developing severe disease compared with placebo.

Coronavirus Update: Drug Shortages On Horizon, Firms Offer Medical Staff For The Fight, More Studies Start

Fears over shortages of drugs needed for ventilated patients rise, while Merck & Co, Pfizer and Lilly allow their medics to volunteer, and attention turns to beta-interferon products and NK cell therapies to fight the virus.

Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist

Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel